Microbix Biosystems Inc. (MBX.TO)
CAD 0.36
(-5.26%)
CAD 0.36
(-5.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -4.96 Million CAD | 35.27% |
| 2022 | -7.66 Million CAD | -240.46% |
| 2021 | -2.25 Million CAD | -137.02% |
| 2020 | 6.08 Million CAD | -11.77% |
| 2019 | 6.89 Million CAD | 10.93% |
| 2018 | 6.21 Million CAD | -13.94% |
| 2017 | 7.22 Million CAD | -1.99% |
| 2016 | 7.36 Million CAD | 3.95% |
| 2015 | 7.08 Million CAD | 31.97% |
| 2014 | 5.37 Million CAD | 8.11% |
| 2013 | 4.96 Million CAD | -25.72% |
| 2012 | 6.68 Million CAD | 13.98% |
| 2011 | 5.86 Million CAD | -1.94% |
| 2010 | 5.98 Million CAD | 19.93% |
| 2009 | 4.98 Million CAD | 902.39% |
| 2008 | 497.8 Thousand CAD | -61.91% |
| 2007 | 1.3 Million CAD | 47.43% |
| 2006 | 886.45 Thousand CAD | 244.19% |
| 2005 | -614.76 Thousand CAD | 5.46% |
| 2004 | -650.29 Thousand CAD | -547.6% |
| 2003 | -100.41 Thousand CAD | 52.74% |
| 2002 | -212.46 Thousand CAD | -52.45% |
| 2001 | -139.36 Thousand CAD | -170.36% |
| 2000 | 198.08 Thousand CAD | -60.38% |
| 1999 | 500 Thousand CAD | 155.56% |
| 1998 | -900 Thousand CAD | 83.93% |
| 1997 | -5.6 Million CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -6.15 Million CAD | -0.87% |
| 2024 Q3 | -6.45 Million CAD | -4.78% |
| 2024 Q1 | -6.1 Million CAD | -23.06% |
| 2023 FY | -4.96 Million CAD | 35.27% |
| 2023 Q1 | -6.45 Million CAD | 15.74% |
| 2023 Q2 | -5.17 Million CAD | 19.81% |
| 2023 Q4 | -4.96 Million CAD | 27.52% |
| 2023 Q3 | -6.84 Million CAD | -32.16% |
| 2022 Q1 | -4.34 Million CAD | -92.89% |
| 2022 Q4 | -7.66 Million CAD | 7.92% |
| 2022 FY | -7.66 Million CAD | -240.46% |
| 2022 Q2 | -5.84 Million CAD | -34.66% |
| 2022 Q3 | -8.32 Million CAD | -42.35% |
| 2021 Q2 | 4.78 Million CAD | -16.4% |
| 2021 Q3 | -1.17 Million CAD | -124.46% |
| 2021 Q1 | 5.72 Million CAD | -5.86% |
| 2021 FY | -2.25 Million CAD | -137.02% |
| 2021 Q4 | -2.25 Million CAD | -92.26% |
| 2020 Q4 | 6.08 Million CAD | 6.09% |
| 2020 FY | 6.08 Million CAD | -11.77% |
| 2020 Q3 | 5.73 Million CAD | -5.48% |
| 2020 Q2 | 6.06 Million CAD | -16.57% |
| 2020 Q1 | 7.26 Million CAD | 5.45% |
| 2019 FY | 6.89 Million CAD | 10.93% |
| 2019 Q1 | 6.26 Million CAD | 0.84% |
| 2019 Q2 | 6.74 Million CAD | 7.69% |
| 2019 Q4 | 6.89 Million CAD | -3.06% |
| 2019 Q3 | 7.11 Million CAD | 5.37% |
| 2018 Q2 | 6.1 Million CAD | -2.46% |
| 2018 Q4 | 6.21 Million CAD | -2.65% |
| 2018 FY | 6.21 Million CAD | -13.94% |
| 2018 Q1 | 6.25 Million CAD | -13.32% |
| 2018 Q3 | 6.38 Million CAD | 4.55% |
| 2017 FY | 7.22 Million CAD | -1.99% |
| 2017 Q4 | 7.22 Million CAD | 7.38% |
| 2017 Q3 | 6.72 Million CAD | -3.25% |
| 2017 Q2 | 6.95 Million CAD | 3.3% |
| 2017 Q1 | 6.72 Million CAD | -8.68% |
| 2016 Q4 | 7.36 Million CAD | -0.87% |
| 2016 FY | 7.36 Million CAD | 3.95% |
| 2016 Q1 | 7.27 Million CAD | 2.58% |
| 2016 Q2 | 7.42 Million CAD | 2.15% |
| 2016 Q3 | 7.43 Million CAD | 0.08% |
| 2015 Q1 | 5.72 Million CAD | 6.54% |
| 2015 Q3 | 6.63 Million CAD | 22.59% |
| 2015 Q2 | 5.41 Million CAD | -5.41% |
| 2015 FY | 7.08 Million CAD | 31.97% |
| 2015 Q4 | 7.08 Million CAD | 6.82% |
| 2014 Q3 | 5.78 Million CAD | 14.65% |
| 2014 Q4 | 5.37 Million CAD | -7.18% |
| 2014 Q2 | 5.04 Million CAD | -2.12% |
| 2014 FY | 5.37 Million CAD | 8.11% |
| 2014 Q1 | 5.15 Million CAD | 3.79% |
| 2013 Q4 | 4.96 Million CAD | -28.49% |
| 2013 Q1 | 6.7 Million CAD | 0.21% |
| 2013 FY | 4.96 Million CAD | -25.72% |
| 2013 Q2 | 6.91 Million CAD | 3.1% |
| 2013 Q3 | 6.94 Million CAD | 0.53% |
| 2012 Q4 | 6.68 Million CAD | 22.48% |
| 2012 FY | 6.68 Million CAD | 13.98% |
| 2012 Q3 | 5.46 Million CAD | -2.8% |
| 2012 Q2 | 5.61 Million CAD | -4.78% |
| 2012 Q1 | 5.9 Million CAD | 0.55% |
| 2011 Q1 | 5.56 Million CAD | -6.93% |
| 2011 FY | 5.86 Million CAD | -1.94% |
| 2011 Q4 | 5.86 Million CAD | -4.1% |
| 2011 Q3 | 6.11 Million CAD | -0.37% |
| 2011 Q2 | 6.14 Million CAD | 10.28% |
| 2010 FY | 5.98 Million CAD | 19.93% |
| 2010 Q4 | 5.98 Million CAD | 6.46% |
| 2010 Q2 | 4.92 Million CAD | -11.24% |
| 2010 Q3 | 5.62 Million CAD | 14.03% |
| 2010 Q1 | 5.55 Million CAD | 11.3% |
| 2009 Q3 | 4.71 Million CAD | 7.99% |
| 2009 Q4 | 4.98 Million CAD | 5.91% |
| 2009 Q1 | 2.88 Million CAD | 479.02% |
| 2009 FY | 4.98 Million CAD | 902.39% |
| 2009 Q2 | 4.36 Million CAD | 51.36% |
| 2008 Q4 | 497.8 Thousand CAD | 1235.2% |
| 2008 Q2 | -2.54 Million CAD | 40.98% |
| 2008 Q1 | -4.3 Million CAD | -429.68% |
| 2008 FY | 497.8 Thousand CAD | -61.91% |
| 2008 Q3 | 37.28 Thousand CAD | 101.47% |
| 2007 Q4 | 1.3 Million CAD | -2.63% |
| 2007 Q1 | 1.51 Million CAD | 70.91% |
| 2007 FY | 1.3 Million CAD | 47.43% |
| 2007 Q2 | 1.79 Million CAD | 18.44% |
| 2007 Q3 | 1.34 Million CAD | -25.2% |
| 2006 FY | 886.45 Thousand CAD | 244.19% |
| 2006 Q4 | 886.45 Thousand CAD | 629.91% |
| 2006 Q3 | 121.44 Thousand CAD | 132.45% |
| 2006 Q2 | -374.3 Thousand CAD | 18.99% |
| 2006 Q1 | -462.04 Thousand CAD | 24.84% |
| 2005 Q4 | -614.76 Thousand CAD | 33.53% |
| 2005 Q3 | -924.81 Thousand CAD | 7.7% |
| 2005 Q2 | -1 Million CAD | -31.76% |
| 2005 Q1 | -760.41 Thousand CAD | -16.93% |
| 2005 FY | -614.76 Thousand CAD | 5.46% |
| 2004 Q4 | -650.29 Thousand CAD | -337.29% |
| 2004 FY | -650.29 Thousand CAD | -547.6% |
| 2004 Q1 | -105.5 Thousand CAD | -5.07% |
| 2004 Q2 | 1121.00 CAD | 101.06% |
| 2004 Q3 | -148.71 Thousand CAD | -13365.83% |
| 2003 Q2 | 220.65 Thousand CAD | 202.58% |
| 2003 Q4 | -100.41 Thousand CAD | -222.85% |
| 2003 Q3 | 81.74 Thousand CAD | -62.96% |
| 2003 FY | -100.41 Thousand CAD | 52.74% |
| 2003 Q1 | -215.09 Thousand CAD | -1.24% |
| 2002 Q1 | -84.12 Thousand CAD | 39.64% |
| 2002 FY | -212.46 Thousand CAD | -52.45% |
| 2002 Q2 | 25.62 Thousand CAD | 130.46% |
| 2002 Q3 | 149.21 Thousand CAD | 482.33% |
| 2002 Q4 | -212.46 Thousand CAD | -242.39% |
| 2001 FY | -139.36 Thousand CAD | -170.36% |
| 2001 Q4 | -139.36 Thousand CAD | -244.71% |
| 2001 Q3 | 96.3 Thousand CAD | -38.91% |
| 2001 Q2 | 157.64 Thousand CAD | -22.25% |
| 2001 Q1 | 202.74 Thousand CAD | 2.35% |
| 2000 Q3 | 300 Thousand CAD | -50.0% |
| 2000 Q2 | 600 Thousand CAD | 50.0% |
| 2000 Q1 | 400 Thousand CAD | -20.0% |
| 2000 FY | 198.08 Thousand CAD | -60.38% |
| 2000 Q4 | 198.08 Thousand CAD | -33.97% |
| 1999 Q1 | -200 Thousand CAD | 77.78% |
| 1999 Q3 | 300 Thousand CAD | 400.0% |
| 1999 Q2 | -100 Thousand CAD | 50.0% |
| 1999 Q4 | 500 Thousand CAD | 66.67% |
| 1999 FY | 500 Thousand CAD | 155.56% |
| 1998 Q2 | -2.5 Million CAD | 45.65% |
| 1998 Q1 | -4.6 Million CAD | 17.86% |
| 1998 FY | -900 Thousand CAD | 83.93% |
| 1998 Q4 | -900 Thousand CAD | 52.63% |
| 1998 Q3 | -1.9 Million CAD | 24.0% |
| 1997 Q2 | 300 Thousand CAD | 150.0% |
| 1997 Q3 | -5.8 Million CAD | -2033.33% |
| 1997 Q4 | -5.6 Million CAD | 3.45% |
| 1997 Q1 | -600 Thousand CAD | 0.0% |
| 1997 FY | -5.6 Million CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Appili Therapeutics Inc. | 8.09 Million CAD | 161.322% |
| Eupraxia Pharmaceuticals Inc. | -11.72 Million CAD | 57.676% |
| Helix BioPharma Corp. | -1.08 Million CAD | -358.942% |
| Medicenna Therapeutics Corp. | -16.98 Million CAD | 70.786% |
| Satellos Bioscience Inc. | -22.06 Million CAD | 77.518% |
| Oncolytics Biotech Inc. | -31.11 Million CAD | 84.053% |
| Sernova Corp. | -8.58 Million CAD | 42.216% |